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onset muscular dystrophy, characterized by progressive myop-
athy, myotonia, and multi-organ involvement. This dystrophy
is an inherited autosomal dominant disease caused by a
(CTG)n expansion within the 30 untranslated region of the
DMPK gene. Expression of the mutated gene results in produc-
tion of toxic transcripts that aggregate as nuclear foci and
sequester RNA-binding proteins, resulting in mis-splicing of
several transcripts, defective translation, and microRNA dysre-
gulation. No effective therapy is yet available for treatment of
the disease. In this study, myogenic cell models were generated
from myotonic dystrophy patient-derived fibroblasts. These
cells exhibit typical disease-associated ribonuclear aggregates,
containing CUG repeats and muscleblind-like 1 protein, and
alternative splicing alterations. We exploited these cell models
to develop new gene therapy strategies aimed at eliminating the
toxic mutant repeats. Using the CRISPR/Cas9 gene-editing sys-
tem, the repeat expansions were removed, therefore preventing
nuclear foci formation and splicing alterations. Compared with
the previously reported strategies of inhibition/degradation of
CUG expanded transcripts by various techniques, the advan-
tage of this approach is that affected cells can be permanently
reverted to a normal phenotype.Received 7 August 2017; accepted 11 October 2017;
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In this work, we describe a genome-editing approach exploited for
deletion of trinucleotide expansion in the dystrophia myotonica pro-
tein kinase (DMPK) gene involved in the pathogenesis of myotonic
dystrophy type 1 (DM1). DM1 is the most common adult-onset
muscular dystrophy,1,2 characterized by progressive skeletal muscle
weakness, myotonia, cardiac defects, smooth muscle dysfunction,
and neurological abnormalities.1–4 The disease is caused by the
expansion of the (CTG)n triplet repeat in the 30 UTR of the DMPK
gene, which encodes for amyosin kinase. This gene is ubiquitously ex-
pressed, but particularly relevant in skeletal and cardiac muscles.2,5
CTG expansion is characterized by high instability, often resultingMolecular Ther
This is an open access article under the CC BY-NC-in increased repeat size with age and in anticipation of symptoms
in successive generations. This tendency of the repeats to further
expand is more pronounced in certain tissues compared to others,
leading to somatic mosaicism.6 The presence of longer repeats corre-
lates with a more severe pathology.7 The molecular effector of the
disease is the DMPKmutant transcript that accumulates into nuclear
aggregates (foci) and sequesters RNA-binding proteins, such as mu-
scleblind-like 1 (MBNL1) protein, involved in the regulation of RNA
splicing.8–10 DM1 molecular pathogenesis also involves changes in
gene expression and translation efficiency, non-conventional transla-
tion, and microRNA deregulation.11–13 Several mouse models of
myotonic dystrophy have been generated, displaying many aspects
of human pathology. These models have contributed to clarify the
disease mechanisms.14–17 Nevertheless, cellular models are still
needed for evaluation of therapeutic molecules or in vitro strategies
and for high-throughput screenings before in vivo validation. DM1
patient-derived cells, both primary cultures and immortalized cell
lines, represent valuable models for these studies because the CTG ex-
pansions are expressed within their native genomic context and the
cells maintain DM1-associated molecular features.18–23 Understand-
ing of the repeated RNA-induced toxicity in DM1 pathogenesis has
led to the rapid development of therapeutic strategies aimed at
neutralizing the toxic RNA. It was shown that the major aspects of
the DM1 phenotype are potentially reversible by targeting the nuclear
CUG repeated mRNA both in cell cultures in vitro and in mouse
models in vivo.24–26 However, these strategies provide only short-
term effects unless repeated administration of the inhibitoryapy: Nucleic Acids Vol. 9 December 2017 ª 2017 The Authors. 337
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Nucleic Acidsmolecules is applied. To date, there is no effective long-term treat-
ment for DM1.
The recent identification of the clustered regularly interspaced short
palindromic repeats (CRISPR)-associated protein 9 (Cas9) system
has revolutionized the field of genetics and has been proposed as a
promising technology to correct the genetic basis of hereditary dis-
eases. CRISPRs were first identified as part of the bacterial immune
system, playing a role in viral defense.27 The CRISPR-associated
endonuclease Cas9 can be targeted to specific locations in the genome
via a RNA-guided system involving single-guide RNAs (sgRNAs) to
induce double-strand breaks in regions of interest.28–30 The double-
strand breaks are preferentially repaired by non-homologous end
joining (NHEJ). When an additional DNA template is provided, a
precise genomic modification can be generated by homology directed
repair (HDR). Although HDR is believed to occur infrequently in
post-mitotic adult tissues,31 such as heart and skeletal muscle, a recent
paper reported HDR-mediated editing in skeletal muscle at a moder-
ate frequency.32 This technology has been recently applied to rescue
the reading frame and expression of dystrophin both in cell models
derived from Duchenne muscular dystrophy (DMD) patients33–35
and inmdxmice in vivo. Dystrophin gene editing resulted in restora-
tion of protein production and improvement of muscle func-
tion.32,36–38 Monogenic diseases resulting from amplification of
genomic sequences, such as DM1, can benefit particularly from the
multiplexing capability of Cas9. In addition, although NHEJ-medi-
ated repair may lead to imperfect or frameshifted repair junction,
the DMPK protein production should not be affected because the re-
peats are located in noncoding regions of theDMPK gene. Indeed, in a
recent paper, published while we were completing our experiments,
CRISPR/Cas9 cleavage ability was described to produce large dele-
tions in DMPK repeat regions in vitro.39 Using a similar approach,
but different Cas9 nuclease and target sequences, we applied the
CRISPR/Cas9 and NHEJ gene-editing system in ad hoc generated
cell models from DM1 patients and succeeded in removing pathoge-
netic CTG expansions permanently, resulting in phenotypic reversion
of the edited cells.
RESULTS
Generation and Characterization of Immortalized Human
Myogenic Cells Derived from Fibroblasts of DM1 Patients
Dermal fibroblasts were derived from2 healthy individuals (CT-A and
CT-B) and 2 DM1 patients diagnosed for displaying abnormal CTG
repeats in the 30 UTR region of the DMPK gene in a single allele
(DM1-A and DM1-B). Fibroblasts were immortalized by infection
with retroviral vectors carrying the human telomerase (TERT) gene
(Figure S1A) and converted to myogenic cells by transduction with
retroviruses producing an inducible myogenic differentiation 1
(MYOD1) transcription factor fused to the estrogen receptor (ER)
hormone binding domain (MYOD1-ER). Cell immortalization is an
essential requirement to allow single cell clonal expansion following
CRISPR/Cas9 treatment. The use ofTERT to immortalize primary hu-
man cells and bypass senescence was demonstrated to be safe because
immortalized cells showed a normal karyotype and no evidence of338 Molecular Therapy: Nucleic Acids Vol. 9 December 2017cancer-associated changes.40,41 After addition of b-estradiol to culture
medium, MYOD1-ER translocates to the nucleus and transactivates
muscle-specific genes (Figure S1B).We did not observe significant dif-
ferences in differentiation and fusion among control and DM1 cell
lines, as determined by immunofluorescence (Figure S2A) and
mRNA/protein expression analyses of muscle-specific transcription
factors and structural genes (Figures S2B and S2C). These findings
are in agreement with previous reports, in which primary or immor-
talized myoblasts derived from healthy individuals and DM1 patients
were used.19,21,22 Differentiated myotubes obtained after MYOD1 in-
duction were analyzed by fluorescent in situ hybridization (FISH) of
ribonuclear inclusions containing CUG repeats (nuclear foci), a hall-
mark of DM1 cell nuclei, through hybridization with a fluorescent
(CAG)6CA probe. Staining with antibodies to MBNL1 showed co-
localization of the protein in nuclear aggregates exclusively in DM1
cells (Figure 1A). In addition, alternative splicing of insulin receptor
(INSR) and sarcoplasmic/endoplasmic reticulum calcium ATPase 1
(SERCA1) transcripts, analyzed by RT-PCR, was found to be defective
in DM1 myotubes and muscle biopsies compared to normal controls
(Figure 1B), as previously reported in DM1 cells and tissues.42,43
Design of the CRISPR/Cas9 Constructs to Delete CTG
Expansions
To create genomic deletions of CTG expansions and restore
normal DMPK gene expression and function, we chose to apply the
CRISPR/Cas9 and NHEJ system to the DM1-A myogenic cell line.
In DM1-A and CT-B myogenic cells, PCR amplification ofDMPK re-
peats, followed by Southern blot analysis with a 50 digoxigenin (DIG)-
labeled (CTG)10 probe,
44 resulted in small bands around 150 nt, cor-
responding to fragments containing 5 CTG repeats for the normal
allele of DM1-A and 5 and 13 CTG repeats for the two alleles of
CT-B (Figure S3A). Higher molecular weight products were amplified
from the DM1-A mutated allele (Figure S3A). The number of CTGs
in the mutated allele of the DM1-A patient was 290 in peripheral
blood cells at diagnosis. However, in primary fibroblasts and engi-
neered DM1-A myogenic cells, the number of repeats was much
higher and heterogeneous, ranging from 300 to over one thousand
(Figure S3A). This expansion increase was likely due to somatic
mosaicism and further amplification during cell culturing. In order
to design the sgRNAs for deletion of the CTG repeats in DM1-A cells,
first we ruled out the possibility of sequence divergence due to indi-
vidual variability. We sequenced about 400 bp upstream and down-
stream of the repeated regions in the DMPK locus, mostly within
the 30 UTR, and found no difference between the wild-type (WT)
and mutated allele. In these regions, 4 CRISPR/Cas9 target sequences
of 20 nt, 2 upstream and 2 downstream of the CTG repeats, were
selected and the corresponding sgRNAs were designed to direct effi-
cient site-specific double-strand breaks (Figure 2A). The sgRNAs
were then cloned into the sgRNA expression vector pLB that also ex-
presses GFP. For Cas9 expression, a plasmid encoding the high spec-
ificity SpCas9 nuclease45 was used.
To determine targeting efficiencies of the different sgRNA pairs, we
initially used the human 293FT cells whose DMPK alleles contain
Figure 1. ImmortalizedMyogenic Cells Derived from
DM1 Patients Exhibit Pathologic Ribonuclear
Inclusions and Splicing Alterations
(A) FISH analysis with Texas-Red-labeled (CAG)6CA
probe of control and DM1 cell lines following induction to
differentiation for 5 days. Cells were stained with anti-
MBNL1 antibody and nuclei were counterstained with
Hoechst dye. Co-localization of CUG-containing tran-
scripts andMBNL1 protein is visible in nuclear aggregates
(merge panels). Scale bar, 10 mm. (B) Splicing analysis of
SERCA1 (SERCA1) and INSR (INSR) transcripts in control
and DM1-derived myogenic cells (24 hr following induc-
tion with b-estradiol) and in muscle biopsies. Percentages
of exon inclusion were calculated as the percentage of the
total intensity of both isoform signals, taken as 100%.
www.moleculartherapy.orgfive CTG repeats and sequences of the sgRNA target regions identical
to those of DM1-A cells. 293FT cells were transfected with the Cas9
plasmid and the 4 possible combinations of sgRNA-encoding plasmid
pairs. After 3 days, genomic DNA extracted from each transfected
polyclonal population was amplified by PCR using primers designed
to reveal all possible editing events. In the 293FT cell line, all sgRNA
combinations gave the expected edited products, with comparable ef-
ficiencies (Figure 2B).
Genome Editing Application to Human DM1Cells for Generation
of Clonal Cell Lines with Deleted CTG Expansions
We next tested the sgRNAs for deletion of the CTG expansion in the
DM1-A cell line. Because transfection efficiency was very low in
these cells, we electroporated the cells with the 4 Cas9/sgRNA
plasmid combinations and, 3 days later, selected GFP-positive cells
by flow cytometry. Sorted cells were either grown as polyclonal pop-
ulations or plated as single cells into 96-well plates for clonal expan-
sion. PCR analysis of genomic DNA from the polyclonal cell popu-
lations showed a similar editing efficiency for the 4 sgRNA
combinations (Figure 2C). Note that only amplicons derived from
WT or edited alleles could be obtained with the adopted PCR con-
ditions, whereas large repeat-containing regions were not amplifiedMolecular Theraat detectable levels. The sgRNA combination
sg34-sg589 targeting more distal sequences
relative to the CTG expansions was selected
for further analysis, assuming that CRISPR/
Cas9 activity in regions more distant from
the CTG repeats should be less influenced
by DNA hairpin structures formed by the
repeated sequences. A total of 85 clones were
analyzed by PCR, and 12 of them showed
bands compatible with a deletion in a single
allele or both (14% editing efficiency). The 12
clones were subjected to FISH analysis and
MBNL1 staining to assess the presence of nu-
clear foci (representative clones are shown in
Figure 3A). Seven clones (7, 18, B9, 12, B1,
D5, and C12) were negative for foci and werefurther analyzed by PCR and sequencing to verify the occurrence
of gene editing, along with two undeleted clones (5 and 9); un-
treated parental cell lines (CT-B and DM1-A) were used as controls
(Figure 4A). To confirm deletion of CTG expansions in the selected
clones, genomic DNA was analyzed by long-range PCR, followed by
Southern blot analysis using probes to detect CTGs. PCR reactions
and Southern hybridizations were performed using two different
protocols and both produced very similar results, although with
different PCR efficiencies. For clarity, some samples are shown in
duplicate (Figures 4B and S3B). The amplified repeat regions of
the mutated alleles containing long repeats of heterogeneous size
(higher smeared bands) migrate slower and can be distinguished
from the short repeats of theWT alleles (lower bands). Minor bands
and smears detectable in Southern blots likely arise from inappro-
priate reannealing during PCR reactions. Deletion of CTG repeats
resulted in the lack of amplified bands (Figures 4B and S3B). The
combined results of PCR, Southern hybridization, and sequencing
analyses of CRISPR/Cas9-treated clones are summarized in Table 1
and Figure 4D. In 5 out of 7 clones negative for nuclear foci in FISH
analysis, the mutated alleles were completely deleted (clones 7, 18,
B9, 12, and B1). Clone 7, 18, B9, and 12 maintained WT repeats.
However, in clone 7, an inversion of the WT repeated regionpy: Nucleic Acids Vol. 9 December 2017 339
Figure 2. Design and Application of CRISPR/Cas9
Gene Editing to Normal and Mutant Human Cells
(A) Schematic representation of the exon 15 region of the
DMPK gene targeted for deletion of CTG repeats by
CRISPR/Cas9. sgRNAs specific to different sites up-
stream (sgRNA UP) and downstream (sgRNA DOWN) of
(CTG)n expansion, shown in red, are indicated by arrows
(upper panel). Partial sequence of DMPK exon 15
showing cleavage positions and target sequences of the
sgRNAs (blue) along the 30 UTR; TAG stop codon and
polyadenylation site are highlighted (black box and green
sequence); primer sequences used in PCR analyses are
underlined (lower panel). (B and C) PCR analysis of
genomic DNA from 293FT cells (B) and DM1-A myogenic
cells (C), co-transfected with eSpCas9 and 2 sgRNAs
(1 up and 1 down) plasmids in all 4 possible combinations.
upF and dwR primer position is indicated in (A). Black
arrows indicate amplicons corresponding to the un-
deleted WT alleles; yellow arrowheads indicate the ex-
pected CTG-deleted products; red arrowheads indicate
bands likely resulting from heteroduplexes formed by the
deletion product strand and unmodified strand. 100-bp
ladder molecular weight markers are shown. Note that
only WT or edited alleles are visible on gels because
large repeats are not amplified efficiently in these PCR
conditions.
Molecular Therapy: Nucleic Acidsoccurred. In clone 12, only one PCR product was detectable when
distal primers were used, suggesting deletions in both alleles (Fig-
ure 4A). However, PCR with primers adjacent to the repeats, fol-
lowed by Southern hybridization, identified a band corresponding
to the WT repeat size (Figures 4B and S3B). Further PCR and
sequencing analysis demonstrated that the WT allele contained a
big insertion in the sg34 target site, explaining why it could be
not amplified by the PCR conditions previously used (Figure 4A).
In clone B1, both the mutated and WT alleles were deleted (Figures
4A and 4B). Clone D5 showed repeat deletion in the WT allele and
inversion of partial CTG expansion with additional insertions in the
mutated allele. Clone C12 showed repeat deletion in the WT allele
and inversion of the entire repeat expansion of the mutated allele.
Interestingly, small indels in one or both sgRNA target sites were
revealed by sequence analysis also in undeleted regions. CRISPR-
Cas9 editing events leading to CTG-repeat deletions resulted in340 Molecular Therapy: Nucleic Acids Vol. 9 December 2017re-joining of the double-strand breaks at
cleavage sites either without indels or with in-
dels, ranging from 1 to 151 nt (Table 1).
To test whether gene editing altered the
expression of the DMPK gene, Northern blot
analysis of untreated and CRISPR/Cas9-
treated clones was performed. Hybridization
with a probe to the DMPK coding region
allowed detection of the expected transcripts
(WT, expanded, deleted, and inverted), with
the exception of clone 12 and D5, whereonly the deleted mutated and WT transcripts, respectively, were
visible (Figure 4C, top panel). The other transcripts of clones 12
and D5 could not be detected, probably due to low expression
levels. Only transcripts containing large expansions in DM1-A,
clone 5 and 9, could be detected using the (CAG)6 probe (Fig-
ure 4C, middle panel). Clone C12 produced a transcript from the
mutated allele, unaltered in size and visible with the DMPK probe,
but undetectable with the (CAG)6 probe due to the repeat inver-
sion. A GAPDH probe was used as loading control (Figure 4C, bot-
tom panel).
Although infrequent in primary human cells,33,34 CRISPR/Cas9-
induced off-target mutations have been reported.46–48 To verify these
effects in our cell context, analysis of possible off-target induced
mutations was performed by PCR and sequencing of the top seven
homologous sites for each sgRNA determined by COSMID and
Figure 3. CRISPR/Cas9-Mediated Deletion of CTG
Expansions in DM1 Myogenic Clones Results in
Phenotypic Reversion
(A) FISH analysis of CRISPR/Cas9-treated clones
5 and B9 following induction to differentiation for
2 days. Cells were stained with anti-MBNL1 antibody
and nuclei counterstained with Hoechst dye. Co-
localization of CUG-containing transcripts and
MBNL1 protein is visible in nuclear aggregates (merge
panels). Scale bar, 10 mm. (B) Splicing analysis of
SERCA1 (SERCA1) and INSR (INSR) transcripts in
CT-B, DM1-A parental cells, and CRISPR/Cas9-
treated clones. Percentages of exon inclusion, calcu-
lated as in Figure 1, are shown.
www.moleculartherapy.orgCas-OFFinder software (Table S1) in parental DM1-A cells and in
some CRISPR/Cas9-treated clones (clone 9, clone B9, clone B1, and
clone 12). This analysis revealed no off-target mutations in edited
cells (Table S1).
Splicing and Differentiation Analysis in CRISPR/Cas9 Edited
Clones
Clones with or without repeats were further analyzed for re-estab-
lishment of normal splicing function by RT-PCR amplification of
alternatively spliced SERCA1 and INSR transcripts. As expected,
clones negative for nuclear foci and deleted for CTG repeats
exhibited normal splicing of SERCA1 and INSR transcripts
compared to clones positive for foci and retaining full expansions
(Figure 3B). Clone C12 showed a partial phenotype. We then
determined whether the clones with deleted repeats maintained
myogenic differentiation capacity upon MYOD1-ER induction
and expressed DMPK protein. Most clones without repeats differ-
entiated and fused normally, as compared to parental DM1-A and
control CT-B cells and clones with intact repeats (Figures 5A and
5B), and maintained DMPK protein expression (Figure 5C), indi-Molecular Theracating that repeat deletion neither affected
myogenic differentiation capacity nor pro-
duction of DMPK protein. Note that DMPK
protein is barely expressed in the absence of
b-estradiol treatment, in agreement with a
previous report showing detectable DMPK
protein accumulation only in skeletal and
heart tissues and differentiated myoblasts
in culture.49 Only one clone failed to accu-
mulate muscle-specific proteins (clone 12,
Figure 5A); this clone expressed a hor-
mone-insensitive MYOD1-ER protein that
translocated poorly to the nucleus failing to
induce detectable myosin and DMPK gene
expression (Figure S4 and not shown). Clone
D5 could not be analyzed for myogenic dif-
ferentiation because cells underwent senes-
cence upon prolonged passaging in culture.Characteristics of all the CRISPR/Cas9-treated clones are summa-
rized in Table 2.
DISCUSSION
Among genome-editing technologies, the CRISPR/Cas9 gene-editing
system can be easily used to target virtually any genomic location. The
multiplex capability of CRISPR/Cas9 gene editing allows large dele-
tion of unwanted genomic sequences by eliciting two simultaneous
double-strand breaks. This capacity has been recently exploited in
myogenic cell models and inmdxmouse models of DMD by different
research groups.32,36–38 In all cases, CRISPR/Cas9-mediated deletion
resulted in exon skipping and production of a shorter but functional
dystrophin protein in vitro and in rescuing of muscular strength in
diseased animals. In the present study, we tested whether CRISPR/
Cas9 and the NHEJ system can be effectively used to excise CTG re-
peats in DM1 patient-derived cells, leading to normalization of
DMPK gene expression and abrogation of RNA toxicity in edited
cells. To this aim, we generated immortalized myogenic cells from
primary fibroblasts derived from DM1 patients, which can synchro-
nously differentiate and fuse into multinucleated myotubes uponpy: Nucleic Acids Vol. 9 December 2017 341
Figure 4.DMPKGene Editing andmRNAExpression
in CRISPR/Cas9-Treated Clones
(A) PCR analysis of CTG expansions in genomic DNA from
untreated CT-B and DM1-A parental cells and CRISPR/
Cas9 selected clones. Positions of the primers used for
amplification are shown in the scheme. Black arrow in-
dicates amplicons corresponding to the untreated/un-
deleted WT alleles; green arrows indicate the amplifica-
tion products obtained following CTG deletion. The faint
bands above the 500-nt marker are likely due to hetero-
duplexes formed by the deletion product strand and the
unmodified strand. (B) Southern blot hybridization of PCR
products amplified with the primers shown in the scheme
from genomic DNA of CRISPR/Cas9-treated clones and
untreated CT-B and DM1-A cells using a DIG-labeled
(CAG)6 probe. Bands corresponding to WT alleles and
alleles with expansions of multiple sizes can be visualized.
Molecular weight markers are indicated: 700 bp corre-
spond to about 190 triplets, 1,200 bp correspond to
about 340 triplets, and 2,800 bp correspond to about
890 triplets. Sequences of the primers upF and dwR
used in (A) and inF and inR used in (B) are shown un-
derlined in Figure 2A. (C) Northern blot hybridization of
polyadenylated RNA from differentiated myoblasts of
CRISPR/Cas9-treated clones and untreated DM1-A cells
using a probe for the DMPK coding region (DMPK),
a probe for the CTG expansions ((CAG)6), and a
probe for GAPDH (GAPDH) as a loading control. Black
arrows indicate undeleted DMPK WT transcripts; red
arrows indicate undeleted expanded transcripts; green ar-
rows indicate transcripts derived from edited WT or
expanded alleles. (D) Summary of the state of the CTG
repeat regions inDMPKWTandmutated alleles ofCRISPR/
Cas9-treated clones and untreated CT-B and DM1-A, re-
sulting from the experiments showed in (A)–(C) and
sequence analyses. D, deletion; a, inversion; b, insertion.
Molecular Therapy: Nucleic Acidsactivation of an ectopically expressed hormone-inducible MYOD1.
These cells present typical DM1-associated alterations, such as ribo-
nuclear aggregates containing CUG repeats and MBNL1 protein,
and alternative splicing abnormalities. Compared to primary
myoblast cultures, our cell models offer a number of advantages. Fi-
broblasts can be easily obtained from skin biopsies, can be grown
indefinitely by immortalization with TERT, and can be induced to
differentiate synchronously and efficiently by conditional MYOD1
activation. Importantly, these cells maintain their myogenic potential
in the absence of induction, unlike primary myoblasts that tend to
decrease their differentiation efficiency during propagation in culture
because of spontaneous differentiation. Similar cell models of342 Molecular Therapy: Nucleic Acids Vol. 9 December 2017muscular dystrophies have been generated by
other groups for studies on disease mechanisms
and for testing therapeutic strategies.20,22,23
Here, we show that CRISPR/Cas9 and the
NHEJ gene-editing strategy can be successfully
applied to our DM1 cell models and leads to
restoration of a normal phenotype. While we
were completing our experiments, similar re-sults were reported by van Agtmaal et al.,39 with some differences.
Unlike these authors, we used the high specificity SpCas9 nuclease
and designed different sgRNAs pairs to target sequences spanning
about 200 nt upstream and 320 nt downstream the expansion flank-
ing regions. In addition, the cell models were generated from different
donor DM1 patients, from a different tissue and using a different pro-
tocol. Nonetheless, in both studies, editing of the expanded repeats
occurred efficiently, further supporting the robustness and versatility
of the CRISPR/Cas9 and NHEJ gene-editing system. In CRISPR/
Cas9-treated clones, deletions, inversions of the excised repeat re-
gions, and insertions were found. Sequencing analysis of the edited
clones revealed small indels at sgRNA target sites, also in the absence
Table 1. Description of CRISPR/Cas9-Editing Events in WT and Mutated
Alleles
Clone
Number CTG Repeats Indel Types
# 5
not altered in WT and mutated
alleles (WT/mut)
WT, sg34 site: +2 nt
mut, sg34 site: +1 nt
# 9
not altered in WT and mutated
alleles (WT/mut)
WT, sg34 site: 1 nt
mut, sg34 site: +1 nt
# 7
inverted in WT allele and deleted
in mutated allele (WTa/Dmut)
WT, sg34 site: none; sg589
site: none
mut, sg34 site: none; sg589
site: none
# 18
not altered in WT and deleted in
mutated allele (WT/Dmut)
WT, sg34 site: +1 nt
mut, sg34 site: 20 nt; sg589
site: 15 nt
# B9
not altered in WT and deleted in
mutated allele (WT/Dmut)
WT, sg34 site: +1 nt; sg589
site: 26 nt
mut, sg34 site: +1 nt; sg589
site: none
# 12
not altered in WT allele with
insertion in sg34 site and deleted
in mutated allele (WTb/Dmut)
WT, sg34 site: insertion;
sg589 site: 1 nt
mut, sg34 site: none; sg589
site: none
# B1
deleted in WT and mutated
alleles (DWT/Dmut)
WT/mut,c sg34 site: 3 nt;
sg589 site: 151 nt
# D5
deleted in WT allele and
rearranged with inversions/
insertions in mutated allele
(DWT/muta,b)
WT, sg34 site: +1 nt; sg589
site: none
mut, sg34 site: +1 nt; sg589
site: none
# C12
deleted in WT allele and
inverted in mutated allele
(DWT/muta)
WT, sg34 site: none; sg589
site: none
mut, sg34 site: none; sg589
site: none
Only indels derived from detectable re-joining events are indicated. D, deletion.
aInversion
bInsertion
cPCR performed using primers located about 700 nt upstream and downstream the
sgRNA target sites did not produce further amplicons, suggesting that cleavage is iden-
tical in both alleles.
www.moleculartherapy.orgof deletion of the repeat regions. When single cleavage events
occurred in the mutated allele, we did not observe deletion of the
repeat regions, as described by van Agtmaal et al.39 This may be
due to the different positions of the sgRNA target sites, with respect
to the CTG repeats in each case.
Because Cas9 shows occasional off-target activity, we analyzed off-
target editing on selected genomic sites for both sgRNAs in our
CRISPR/Cas9-treated clones and found no effects, confirming previ-
ous reports describing a low tendency of Cas9 to cut on off-target
genomic regions in human patient-derived cells.33,34 However,
considering the number of clones analyzed in our and others’ exper-
iments, inversion, insertions, or other uncontrolled events around
sgRNA on-target sites appear to be rather frequent, raising an impor-tant concern on the future application of this technology in gene ther-
apy. With regard to detrimental Cas9 editing activity, a more strin-
gent analysis of Cas9 off-target effects using, for example, whole
genome sequencing may be necessary to identify off-target sites
that cannot be predicted by sequence comparison. Improvement of
the targeting specificity and adjustable expression of Cas9 nuclease,
both tissue specific and time controlled, will also be important for
therapeutic use because genome editing leads to permanent
modifications.
Recently, a genome therapy approach for DM1 has been applied to
patient-derived induced pluripotent stem cells (iPSCs) using the
site-specific transcription activator-like effector nuclease (TALEN)
to insert a polyA signal upstream of DMPK CTG repeats, producing
a shorter transcript that lacks the repeated region. Treated iPSCs
maintained pluripotency and exhibited a reversed phenotype.50 How-
ever, expanded CTG repeats in the DMPK gene, which have been
shown to affect transcription of adjacent genomic regions,51 were
not removed and, due to sequence constraint for TALEN activity, ed-
iting resulted in the production of a DMPK-truncated protein.
The great advantage and novelty of the CRISPR/Cas9 genome-editing
system is that it makes possible deletions up to several kilobases of
repeated DNA. In addition, it leads to permanent rescue of normal
cell function, in contrast to transient effects observed when using
antisense approaches to repeated transcripts.24–26 Importantly for
future application, we have shown that this technology has no
apparent negative effects in cell cultures because differentiation and
fusion capability were not affected. Likewise, DMPK transcript and
protein production in edited cells were similar to untreated cells.
We did not observe differences in myotube formation among control,
DM1-derived myoblasts, and clones with deleted repeats, in contrast
to van Agtmaal et al.,39 who described increased fusion in their
CRISPR/Cas9-edited myoblasts.39 Our results support previous
work showing that differentiation and fusion are not significantly
different in primary and immortalized myoblasts derived from
DM1 patients or unaffected individuals.19,21 Modest reduction of
fusion capacity in DM1-derived myoblasts has been recently re-
ported,23 and increased apoptosis and autophagy have been observed
in DM1 myotubes after prolonged time in culture.19
Once it is determined that CRISPR/Cas9 can achieve therapeutic
reversal of DM1-related alterations in cell cultures, the next step
will be to test this approach in preclinical models, with the future
goal to apply it in DM patient tissues for somatic gene therapy. The
use of CRISPR/Cas9 gene-editing strategies in animal models will
require the use of improved Cas9 nuclease and sgRNAs, limiting
possible off-target effects. In addition, Cas9 size should be reduced
to fit into the genome of recombinant vectors, such as adeno associ-
ated viral (AAV) vector for in vivo transduction experiments. AAVs
have been successfully engineered as gene-delivery vectors for effi-
cient transduction of post-mitotic cells, including skeletal muscles.52
An interesting AAV vector carrying a short Cas9 (saCas9) under a
muscle-specific promoter and 2 sgRNA expression cassettes in aMolecular Therapy: Nucleic Acids Vol. 9 December 2017 343
Figure 5. CRISPR/Cas9 Edited Clones Maintain Differentiation and Fusion Capacity upon MYOD1-ER Induction
(A) Western blot analysis of muscle-specific myogenin (Myog), myosin (MHC), and constitutively expressed vinculin (Vinculin) in CT-B and DM1-A parental cells and
CRISPR/Cas9-edited clones in the absence or presence of b-estradiol to induce differentiation for 5 days. (B) Immunofluorescence analysis of parental DM1-A
myogenic cells and representative CRISPR/Cas9-treated clones, with (Cl 5 and Cl 9) or without (Cl 7, Cl B9, and Cl B1) CTG expansions, allowed to differentiate for
(legend continued on next page)
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Table 2. Characteristics of CRISPR/Cas9-Edited Clones and Parental Cells
Parental Cells/
Clone Number CTG Repeats Nuclear Foci
Myogenic
Differentiation
DMPK WT/mut
mRNA DMPK Protein
Normal Splicing
SERCA1
Normal Splicing
INSR
CT-B WT/WT  ++ ND + + +
DM1-A WT/mut + +++ +/+ +  
# 5 WT/mut + ++ +/+ +  
# 9 WT/mut + ++ +/+ +  
# 7 WTa/Dmut  ++ +/D+ + + +
# 18 WT/Dmut  +++ +/D+ ++ + +
# B9 WT/Dmut  +++ +/D+ ++ + +/
# 12 WTb/Dmut   /D+ /+ + +
# B1 DWT/Dmut  ++ D+/D+ + + +/
# D5 DWT/muta,b  ND D+/ ND + +
# C12 DWT/muta  ++ D+/+ + + +/
D, deletion; ND, not determined.
aInversion
bInsertion
www.moleculartherapy.orgsingle vector has been recently generated and used for recovering dys-
trophin expression in heart and skeletal muscle ofmdxmice.32 In the
same paper, CRISPR/Cas9 combined with the more specific HDR
repair system has also been exploited and proved functional in muscle
cells, although at a lower efficiency compared to NHEJ.32 Overall, the
results obtained by us and others clearly highlight the potential of the
CRISPR/Cas9 gene-editing strategy as a powerful tool for future gene
therapy application in DM1 pathology.
MATERIALS AND METHODS
Antibodies
Mouse monoclonal antibody (mAb) to humanMBNL1 (3A4), mouse
mAb to human DMPK (9-RY26), and rabbit polyclonal Ab to mouse
MYOD1 (C-20) were from Santa Cruz Biotechnology (Santa Cruz,
CA). Mouse mAb to vinculin was purchased from Sigma-Aldrich
(St. Louis, MO). Mouse mAb to fast myosin heavy chain (MF20)
was obtained from D. Fischman, and mouse mAb to myogenin
(F5D) was a gift from G. Cossu. TRITC-conjugated goat anti-rabbit
antibodies were from Jackson ImmunoResearch Laboratories (West
Grove, PA). Alexa Fluor 488 goat anti-mouse antibody was from
Thermo Fisher Scientific (Waltham, MA). Horseradish-peroxidase-
conjugated goat anti-mouse and anti-rabbit antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA).
Design and Construction of CRISPR/Cas9 Components
For Cas9 expression, we selected a plasmid expressing the Strepto-
coccus pyogenes (Sp) high specificity nuclease (eSpCas9(1.1),45 Addg-
ene #71814, Cambridge, MA). Target sites for CRISPR/Cas9 across
the trinucleotide repeats in exon 15 of DMPK (NCBI, Gene Database,5 days and stained with anti-MHC antibody and Hoechst dye (scale bar, 50 mM). Th
(average ± SE, n R 4). The fusion index is calculated as the percentage of nuclei in
least 300 cells were counted for each cell type in each experiment. (C) Western
CRISPR/Cas9-treated clones, treated as above.GeneID: 1760, nucleotides 45,770,345–45,770,148) were selected
using the CRISPR sgRNA design web tool at: https://portals.
broadinstitute.org/gpp/public/analysis-tools/sgrna-design. Different
target sites were scored based on the number of predicted off-targets
and whether off-targets were perfect hits or contained mismatches.
PCRs for amplification and sequencing of the flanking regions up-
stream and downstream the CTG repeats were performed using
upF and upR and dwF and dwR primers (Table S2). Complementary
DNA oligonucleotides specifying the 20-nt guide RNA sequence and
an optimized Cas9 nuclease-recruiting sequence53 (Table S2) were
cloned into the sgRNA expression vector pLB also expressing GFP
(Addgene #11619) (Cambridge, MA). Proper insertion of the oligo-
nucleotides into the vector was verified by sequencing.
Cell Culture, Viral Infections, and DNA Transfection
Immortalized human myoblasts CT-A and CT-B were derived from
primary dermal fibroblasts of control individuals unaffected with
DM1. Immortalized human DM1 myogenic cells DM1-A and
DM1-B were derived from primary dermal fibroblasts of two DM1
patients, with one DMPK normal allele and one mutated allele con-
taining 290 and 520 CTG amplifications at diagnosis, respectively.
All human specimens were obtained after receiving written informed
consent. This study was authorized by the Institutional Ethics Com-
mittee (ASL MI2-Melegnano via VIII Giugno, Milan) and was con-
ducted in accordance with the principles expressed in the Declaration
of Helsinki, the institutional regulation, and Italian laws and guide-
lines. The skin biopsies were cut into small pieces and placed into
an empty 10-cm Petri dish for approximately 10–15 min to promote
attachment. Then sufficient growth medium (DMEM supplementede fusion index and percentage of MHC-positive cells is shown in the table below
MHC-positive myotubes (containingR2 nuclei) over the total number of cells. At
blot analysis of DMPK and vinculin in DM1-A parental cells and representative
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midified incubator at 37C and 5% CO2 atmosphere. The medium
was changed every 2 to 3 days to remove cell debris and maintain a
physiological pH. Skin explants were kept in culture for a few weeks
and transferred to new dishes every week to allow complete fibroblast
outgrowth. Cells were grown to confluence and then removed by
trypsinization, counted, and cryopreserved. Fibroblasts were sequen-
tially infected with retroviral vectors carrying TERT and Hygromicin
selection54 (Addgene #1773) (Cambridge, MA), and with retroviruses
carrying estrogen-inducible mouseMyod1 and puromicin selection55
(Addgene #13494) (Cambridge, MA). TERT- and MYOD1-express-
ing cells were propagated in DMEM without phenol red (Gibco,
Thermo Fisher Scientific, Waltham, MA) supplemented with 15%
FBS (Gibco, Thermo Fisher Scientific,Waltham,MA). Differentiation
to myotubes was induced by growing cells to confluency on dishes
coated with 0.5% gelatin (Sigma-Aldrich, St. Louis, MO) and replac-
ing the proliferation medium with differentiation medium consisting
of DMEM without phenol red supplemented with 10 mg/mL insulin
(Sigma-Aldrich, St. Louis, MO), 100 mg/mL transferrin (Gibco,
Thermo Fisher Scientific, Waltham, MA), and 107 M b-estradiol
(Sigma-Aldrich, St. Louis, MO). Human 293FT cells were propagated
in DMEM (Gibco, Thermo Fisher Scientific, Waltham, MA) supple-
mented with 10% FBS. All cells were incubated under a 5%CO2 atmo-
sphere at 37C. Cell trasfection of 293FT cells was performed with
Lipofectamin 2000 (Invitrogen, Thermo Fisher Scientific, Carlsbad,
CA), whereas myoblasts were electroporated according to the manu-
facturers’ instructions (Amaxa Basic Nucleofector Kit VP1-1002,
Lonza, Basel, Switzerland). Electroporated cells co-expressing GFP
were sorted by flow cytometry at the Flow Cytometry Facility at
EMBL, Monterotondo, Italy.
Northern Blot Analysis
Polyadenylated mRNA was isolated from differentiated myoblasts
using the GeneElute Direct mRNA Miniprep kit (Sigma-Aldrich,
St. Louis, MO), following the manufacturer’s instructions. Northern
blotting was performed according to standard procedures. 1 to 2 mg
of polyadenylated RNA was subjected to electrophoresis in a
1.2% agarose gel under denaturing conditions. RNA was trans-
ferred to positively charged nylon membranes (Roche, Sigma-
Aldrich, St. Louis, MO) by capillary transfer in 20  SSC and
hybridized with 50 DIG-labeled (CAG)6 LNA-oligonucleotide (Euro-
gentec, Liège, Belgium) and with DIG-labeled probes to DMPK
(NM_001081563.2, nt 1145-1526) and GAPDH (NM_001289745,
nt 133-617), generated with DIG-High Prime (Roche, Sigma-Aldrich,
St. Louis, MO) according to the random primed labeling technique.
The probe-target hybrids were visualized by chemiluminescent assay
using the CDP-Star substrate (Roche, Sigma-Aldrich, St. Louis, MO)
and the ChemiDoc Imaging System (Bio-Rad, Hercules, CA).
Long PCR and Southern Blot Hybridization
First protocol: long PCR was performed as previously described44 us-
ing the Myotonic Dystrophy SB kit (Experteam, Venice, Italy) with
100 ng genomic DNA for each cell line. PCR conditions were one cy-
cle of 1 min at 94C; 28 cycles of 20 s at 94C and 7 min at 62C; and346 Molecular Therapy: Nucleic Acids Vol. 9 December 2017finally 10 min at 72C. For Southern blot analysis, PCR products were
separated by electrophoresis on 1% agarose gels, along with DIG-
labeled DNA molecular weight markers VII and VIII (Roche,
Sigma-Aldrich, St. Louis, MO), transferred to nylon membranes
(Roche, Sigma-Aldrich, St. Louis, MO), and hybridized overnight
with a nonradioactive Digoxigenin-based probe, 50 DIG-labeled
(CTG)10 according to manufacturer instructions (Roche, Sigma-Al-
drich, St. Louis, MO). Second protocol: genomic DNA was digested
with BamHI restriction enzyme and 15 ng were amplified using
primers inF and inR (Table S2). PCR conditions were one cycle of
10 min at 95C; 28 cycles of 45 s at 95C, 45 s at 65C, and 3 min at
72C; and finally 45 s at 65C and 10 min at 72C. PCR products
were separated on 1.5% agarose gels, along with DIG-labeled markers
VII. Hybridization was performed as previously reported56 using a
50 DIG-labeled (CAG)6 LNA probe. The chemiluminescence signal
was visualized on the ChemiDoc Instrument (Bio-Rad, Hercules, CA).
PCR Amplification Analysis of On-Target and Off-Target
Genome-Editing Events
Amplifications of the on-target regions of the edited polyclonal
population and individual clones were performed from genomic
DNA using the KAPA2G Fast HS Genotyping Mix (2X) (Roche,
Sigma-Aldrich, St. Louis, MO), with specifically designed primers
(upF and dwR; Table S2). The putative off-target sites corresponding
to different genomic locations for sg34 and sg589 were determined by
COSMID public software at https://CRISPR.bme.gatech.edu/,48
adopting the following criteria: NGG PAM, 3 mismatches with no in-
dels and 2 mismatches with 1-base deletions or insertions. Genomic
DNA extracted from the parental and four different edited clonal
cell lines was amplified using the KAPA2G Fast HS Genotyping
Mix (2X) (Roche, Sigma-Aldrich, St. Louis, MO), with primers spe-
cific for 7 top potential off-target sites (Table S2). The selected sites
were also identified by the Cas-OFFinder software (http://www.
rgenome.net/cas-offinder). Primer synthesis and sequencing were
performed by Eurofins Scientific (Luxembourg, Luxembourg). DNA
sequences were aligned using Clustal Omega-Multiple Sequence
Alignment public software (EMBL-EBI, Hinxton, UK).
RNA Analysis by RT-PCR
RNAs from polyclonal and clonal cell lines were extracted with
TRIzol reagent (Invitrogen, Thermo Scientific, Carlsbad, CA) and
retro-transcribed with the SuperScript IV First-Strand Synthesis Sys-
tem (Invitrogen) using oligo (dT) and random primers. All RT-PCR
analyses were performed using GoTaq Flexi DNA Polymerase (Prom-
ega, Fitchburg, WI) for 35 cycles using the specific primers listed in
Table S2. Quantitation of amplified bands on gel images was per-
formed using ImageJ software. Exon inclusion was quantified as the
percentage of the total intensity of isoform signals.
RNA FISH and Immunofluorescence Staining
Cells were fixed with 2% formaldehyde and subjected to FISH using a
(CAG)6 probe labeled with Texas Red at the 50 end (IDT, Coralville,
IA) in combination with immunofluorescence staining, as described
previously.56 To verify the co-localization of MBNL1 in ribonuclear
www.moleculartherapy.orginclusions, following the last post-hybridization wash, cells were incu-
bated in PBS containing 3% BSA for 15 min and stained sequentially
with antibodies to MBNL1, diluted 1:250 in PBS containing 3% BSA,
and with goat anti-mouse antibody conjugated Alexa Fluor 488. For
labeling with antibodies to MHC and MYOD1, cultures were fixed
with 80% acetone and washed thoroughly before incubation with pri-
mary and secondary antibody. Nuclei were visualized with Hoechst
33258 dye. The samples were examined with an Olympus AX70
immunofluorescence microscope. Images were recorded on an
Olympus XM10 camera and processed using the Olympus CellSens
Standard 1.8.1 software. Cell scoring was carried out using ImageJ
software.
Whole-Cell Extracts and Western Blot Analysis
Cells were lysed in RIPA buffer (140 mM NaCl, 3 mMMgCl2, 1 mM
EDTA, and 15 mM HEPES, pH 7.2, also containing 0.5% sodium de-
oxycholate, 1% NP-40, and 0.1% SDS) supplemented with a cocktail
of protease inhibitors (Roche, Sigma-Aldrich, St. Louis, MO). West-
ern blots were carried out using horseradish-peroxidase-conjugated
goat anti-rabbit and anti-mouse antibodies and revealed with a chem-
iluminescence detection system by Cyanagen (Bologna, Italy). Imag-
ing and quantitation of the bands were carried out by the ChemiDoc
XRS Western Blot Imaging System using the ImageLab 4.0 software
(Bio-Rad, Hercules, CA).
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